Revenue increased 13.2%
Revenue changed +13.2% from the comparable as-filed period.
$95.5M→$108.1M2 prior comparisons
GROSSPATTERN / DETERMINISTIC EVIDENCE / V3
Search securities →AMBA financial changes
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Research & development decreased 15.3%
Research & development changed -15.3% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
$59.7M→$50.6M2 prior comparisons
Receivables / revenue moved 1029 bp lower
Receivables / revenue changed -1029 basis points from the comparable as-filed period.
44.91%→34.63%2 prior comparisons
R&D / revenue moved 1576 bp lower
R&D / revenue changed -1576 basis points from the comparable as-filed period.
62.54%→46.78%2 prior comparisons
Gross margin moved 115 bp lower
Gross margin changed -115 basis points from the comparable as-filed period.
58.87%→57.73%2 prior comparisons
Trade receivables decreased 12.7%
Trade receivables changed -12.7% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
$42.9M→$37.4M4 prior comparisons
Current assets increased 14.6%
Current assets changed +14.6% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
$343.9M→$394.0M4 prior comparisons
Total assets increased 10.4%
Total assets changed +10.4% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
$706.4M→$780.2M4 prior comparisons
Current liabilities increased 9.9%
Current liabilities changed +9.9% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
$125.9M→$138.4M4 prior comparisons
Gross profit increased 11.0%
Gross profit changed +11.0% from the comparable as-filed period.
$56.2M→$62.4M2 prior comparisons
Shares outstanding increased 3.4%
Shares outstanding changed +3.4% from the comparable as-filed period. The change ranks at the 25th percentile of 8 prior comparable changes.
42,689,006→44,140,9718 prior comparisons
Stock-based compensation decreased 9.9%
Stock-based compensation changed -9.9% from the comparable as-filed period.
$25.2M→$22.7M2 prior comparisons
Current ratio increased 4.3%
Current ratio changed +4.3% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
2.73→2.854 prior comparisons
Selling, general & administrative increased 8.1%
Selling, general & administrative changed +8.1% from the comparable as-filed period.
$18.5M→$20.0M2 prior comparisons
Gross margin moved 163 bp lower
Gross margin changed -163 basis points from the comparable as-filed period.
60.01%→58.38%3 prior comparisons
Cash & equivalents decreased 19.0%
Cash & equivalents changed -19.0% from the comparable as-filed period.
$141.3M→$114.4M2 prior comparisons
Gross profit increased 13.7%
Gross profit changed +13.7% from the comparable as-filed period.
$51.5M→$58.6M3 prior comparisons
Stock-based compensation decreased 16.2%
Stock-based compensation changed -16.2% from the comparable as-filed period.
$26.1M→$21.9M3 prior comparisons
Capex / revenue moved 137 bp lower
Capex / revenue changed -137 basis points from the comparable as-filed period.
5.32%→3.94%2 prior comparisons
Research & development decreased 1.2%
Research & development changed -1.2% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
$58.8M→$58.1M3 prior comparisons
Selling, general & administrative increased 6.9%
Selling, general & administrative changed +6.9% from the comparable as-filed period.
$18.6M→$19.9M3 prior comparisons
Capital expenditure decreased 13.3%
Capital expenditure changed -13.3% from the comparable as-filed period. The change ranks at the 0th percentile of 6 prior comparable changes.
$4.6M→$4.0M6 prior comparisons
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.